| cGVHD | Ruxolitinib (11) | Ibrutinib (7) | Imatinib (10) |
|---|---|---|---|
| Steroid-dependent cGVHD | 3 | 0 | 3 |
| Median dose of steroids at time of initial treatment (mg/kg/die) | 1 (0.5-1) | 0 | 0.5 (0.1-1) |
| Median dose of steroids after 3 months of treatment (mg/kg/die) | 0.2 (0-0.4) | 0 | 0.3 |
| Number of patients discontinuing steroids | 2 (67%) | 0 | 2 (67%) |
| Steroid-refractory cGVHD | 8 | 7 | 7 |
| ORR | 37.5% (1CR, 2 PR) | 43% (3 PR) | 14% (1 PR) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.